Federal Register Notice: FDA’s Nonprescription Drugs Advisory Committee will meet 7/31, from 8 a.m. to 5 p.m. at the DoubleTree by Hilton Hotel Washington DC/Silver Spring, The Ballrooms, 8727 Colesville Rd., Silver Spring, MD. The committee will Sanofi-aventis data submitted to support a supplemental NDA for the switch from prescription to OTC of triamcinolone acetonide nasal spray. The proposed OTC use is “temporarily relieves these symptoms of hay fever or other upper respiratory allergies: Nasal congestion, runny nose, sneezing, itchy nose.” Contact Glendolynn S. Johnson, (301) 796-9001. To view this notice, click here.